Smartphone-Based Virtual Agents to Help Individuals With Sleep Concerns During COVID-19 Confinement: Feasibility Study.


Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
18 12 2020
Historique:
received: 11 09 2020
accepted: 30 11 2020
revised: 26 10 2020
pubmed: 3 12 2020
medline: 5 1 2021
entrez: 2 12 2020
Statut: epublish

Résumé

The COVID-19 crisis and consequent confinement restrictions have caused significant psychosocial stress and reports of sleep complaints, which require early management, have increased during recent months. To help individuals concerned about their sleep, we developed a smartphone-based app called KANOPEE that allows users to interact with a virtual agent dedicated to autonomous screening and delivering digital behavioral interventions. Our objective was to assess the feasibility of this app, in terms of inclusion rate, follow-up rate, perceived trust and acceptance of the virtual agent, and effects of the intervention program, in the context of COVID-19 confinement in France. The virtual agent is an artificial intelligence program using decision tree architecture and interacting through natural body motion and natural voice. A total of 2069 users aged 18 years and above downloaded the free app during the study period (April 22 to May 5, 2020). These users first completed a screening interview based on the Insomnia Severity Index (ISI) conducted by the virtual agent. If the users were positive for insomnia complaints (ISI score >14), they were eligible to join the 2-stage intervention program: (1) complete an electronic sleep diary for 1 week and (2) follow personalized sleep recommendations for 10 days. We collected and analyzed the following measures: sociodemographic information, ISI scores and sleep/wake schedules, and acceptance and trust of the agent. Approximately 76% (1574/2069) of the app users completed the screening interview with the virtual agent. The virtual agent was well accepted by 27.4% (431/1574) of the users who answered the acceptance and trust questionnaires on its usability, satisfaction, benevolence, and credibility. Of the 773 screened users who reported sleep complaints (ISI score >14), 166 (21.5%) followed Step 1 of the intervention, and only 47 of those (28.3%) followed Step 2. Users who completed Step 1 found that their insomnia complaints (baseline mean ISI score 18.56, mean ISI score after Step 1 15.99; P<.001) and nocturnal sleep quality improved significantly after 1 week. Users who completed Step 2 also showed an improvement compared to the initial measures (baseline mean ISI score 18.87, mean ISI score after Step 2 14.68; P<.001). Users that were most severely affected (ISI score >21) did not respond to either intervention. These preliminary results suggest that the KANOPEE app is a promising solution to screen populations for sleep complaints and that it provides acceptable and practical behavioral advice for individuals reporting moderately severe insomnia.

Sections du résumé

BACKGROUND
The COVID-19 crisis and consequent confinement restrictions have caused significant psychosocial stress and reports of sleep complaints, which require early management, have increased during recent months. To help individuals concerned about their sleep, we developed a smartphone-based app called KANOPEE that allows users to interact with a virtual agent dedicated to autonomous screening and delivering digital behavioral interventions.
OBJECTIVE
Our objective was to assess the feasibility of this app, in terms of inclusion rate, follow-up rate, perceived trust and acceptance of the virtual agent, and effects of the intervention program, in the context of COVID-19 confinement in France.
METHODS
The virtual agent is an artificial intelligence program using decision tree architecture and interacting through natural body motion and natural voice. A total of 2069 users aged 18 years and above downloaded the free app during the study period (April 22 to May 5, 2020). These users first completed a screening interview based on the Insomnia Severity Index (ISI) conducted by the virtual agent. If the users were positive for insomnia complaints (ISI score >14), they were eligible to join the 2-stage intervention program: (1) complete an electronic sleep diary for 1 week and (2) follow personalized sleep recommendations for 10 days. We collected and analyzed the following measures: sociodemographic information, ISI scores and sleep/wake schedules, and acceptance and trust of the agent.
RESULTS
Approximately 76% (1574/2069) of the app users completed the screening interview with the virtual agent. The virtual agent was well accepted by 27.4% (431/1574) of the users who answered the acceptance and trust questionnaires on its usability, satisfaction, benevolence, and credibility. Of the 773 screened users who reported sleep complaints (ISI score >14), 166 (21.5%) followed Step 1 of the intervention, and only 47 of those (28.3%) followed Step 2. Users who completed Step 1 found that their insomnia complaints (baseline mean ISI score 18.56, mean ISI score after Step 1 15.99; P<.001) and nocturnal sleep quality improved significantly after 1 week. Users who completed Step 2 also showed an improvement compared to the initial measures (baseline mean ISI score 18.87, mean ISI score after Step 2 14.68; P<.001). Users that were most severely affected (ISI score >21) did not respond to either intervention.
CONCLUSIONS
These preliminary results suggest that the KANOPEE app is a promising solution to screen populations for sleep complaints and that it provides acceptable and practical behavioral advice for individuals reporting moderately severe insomnia.

Identifiants

pubmed: 33264099
pii: v22i12e24268
doi: 10.2196/24268
pmc: PMC7752183
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e24268

Informations de copyright

©Pierre Philip, Lucile Dupuy, Charles M Morin, Etienne de Sevin, Stéphanie Bioulac, Jacques Taillard, Fuschia Serre, Marc Auriacombe, Jean-Arthur Micoulaud-Franchi. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 18.12.2020.

Références

Front Psychiatry. 2020 May 28;11:511
pubmed: 32670100
NPJ Digit Med. 2020 Jan 7;3:2
pubmed: 31934646
Sleep Med Rev. 2016 Dec;30:1-10
pubmed: 26615572
JAMA. 1984 Oct 12;252(14):1905-7
pubmed: 6471323
Sci Rep. 2017 Feb 16;7:42656
pubmed: 28205601
J Med Internet Res. 2020 Jun 16;22(6):e19284
pubmed: 32501804
J Sleep Res. 2021 Apr;30(2):e13094
pubmed: 32557996
JMIR Ment Health. 2020 Jul 6;7(7):e19246
pubmed: 32484783
Sleep. 2012 Jun 01;35(6):769-81
pubmed: 22654196
Sleep Med. 2001 Jul;2(4):297-307
pubmed: 11438246
Neuropsychopharmacology. 2003 Feb;28(2):359-70
pubmed: 12589389
Lancet. 2020 Mar 14;395(10227):912-920
pubmed: 32112714
Sleep. 2006 Sep;29(9):1155-73
pubmed: 17040003
Int J Eat Disord. 2020 Jul;53(7):1155-1157
pubmed: 32449523
Psychiatry Res. 2016 Mar 30;237:196-200
pubmed: 26809367
Sleep. 2006 Jan;29(1):85-93
pubmed: 16453985
Appl Nurs Res. 2011 Feb;24(1):53-8
pubmed: 20974066
Sleep. 2011 May 01;34(5):601-8
pubmed: 21532953
Arch Gen Psychiatry. 2009 Jul;66(7):692-8
pubmed: 19581560
Indian J Public Health. 2020 Jun;64(Supplement):S117-S124
pubmed: 32496240
JAMA Psychiatry. 2019 Jan 1;76(1):21-30
pubmed: 30264137
Drug Alcohol Depend. 2018 Dec 1;193:1-6
pubmed: 30321739
JAMA. 2017 Oct 3;318(13):1215-1216
pubmed: 28973224
Sleep Med. 2021 Jan;77:346-347
pubmed: 32595107
Psychiatry Res. 2020 Jul;289:113076
pubmed: 32434093
Int J Environ Res Public Health. 2020 Jun 07;17(11):
pubmed: 32517294
JAMA. 2015 Apr 28;313(16):1619-20
pubmed: 25799162

Auteurs

Pierre Philip (P)

USR 3413 SANPSY, University of Bordeaux, Bordeaux, France.
Service de Médecine du Sommeil, University Hospital of Bordeaux, Bordeaux, France.
SANPSY, USR 3413, Centre Nationale de la Recherche Scientifique, Bordeaux, France.

Lucile Dupuy (L)

USR 3413 SANPSY, University of Bordeaux, Bordeaux, France.
SANPSY, USR 3413, Centre Nationale de la Recherche Scientifique, Bordeaux, France.

Charles M Morin (CM)

Ecole de psychologie, Université Laval, Quebec, QC, Canada.
Centre d'étude des troubles du sommeil, Centre de recherche CERVO, Institut universitaire en santé mentale de Québec, Québec, QC, Canada.

Etienne de Sevin (E)

USR 3413 SANPSY, University of Bordeaux, Bordeaux, France.
SANPSY, USR 3413, Centre Nationale de la Recherche Scientifique, Bordeaux, France.

Stéphanie Bioulac (S)

USR 3413 SANPSY, University of Bordeaux, Bordeaux, France.
Service de Médecine du Sommeil, University Hospital of Bordeaux, Bordeaux, France.
SANPSY, USR 3413, Centre Nationale de la Recherche Scientifique, Bordeaux, France.

Jacques Taillard (J)

USR 3413 SANPSY, University of Bordeaux, Bordeaux, France.
SANPSY, USR 3413, Centre Nationale de la Recherche Scientifique, Bordeaux, France.

Fuschia Serre (F)

USR 3413 SANPSY, University of Bordeaux, Bordeaux, France.
SANPSY, USR 3413, Centre Nationale de la Recherche Scientifique, Bordeaux, France.

Marc Auriacombe (M)

USR 3413 SANPSY, University of Bordeaux, Bordeaux, France.
SANPSY, USR 3413, Centre Nationale de la Recherche Scientifique, Bordeaux, France.

Jean-Arthur Micoulaud-Franchi (JA)

USR 3413 SANPSY, University of Bordeaux, Bordeaux, France.
Service de Médecine du Sommeil, University Hospital of Bordeaux, Bordeaux, France.
SANPSY, USR 3413, Centre Nationale de la Recherche Scientifique, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH